BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fico G, Isayeva U, De Prisco M, Oliva V, Solè B, Montejo L, Grande I, Arbelo N, Gomez-Ramiro M, Pintor L, Carpiniello B, Manchia M, Vieta E, Murru A. Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis. Eur Neuropsychopharmacol 2023;66:30-44. [PMID: 36399837 DOI: 10.1016/j.euroneuro.2022.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Bartova L, Dold M, Fugger G, Weidenauer A, Rujescu D, Kasper S. Silexan for treatment of anxiety and depression in the context of COVID-19. Eur Neuropsychopharmacol 2023;70:47-8. [PMID: 36867894 DOI: 10.1016/j.euroneuro.2023.02.015] [Reference Citation Analysis]
2 Boretti A. Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe. Eur Neuropsychopharmacol 2023;67:83-5. [PMID: 36640691 DOI: 10.1016/j.euroneuro.2022.12.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kenji Hashimoto. Overview of the potential use of fluvoxamine for COVID-19 and long COVID. Discov Ment Health 2023;3:9. [ DOI: 10.1007/s44192-023-00036-3] [Reference Citation Analysis]